Millennium And Morphosys Extend Collaboration

Millennium Pharmaceuticals, Inc. has signed an agreement for an expanded alliance with MorphoSys AG. Under their agreement, MorphoSys AG will apply its proprietary HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium. One of the objectives of the alliance is to develop fully human antibodies against targets Read more about Millennium And Morphosys Extend Collaboration[…]

Millennium And Lilly Extend Collaboration

Millennium Pharmaceuticals, Inc. and Eli Lilly and Company have announced a one-year extension of their cardiovascular disease research collaboration. The five-year partnership, originally due to expire in October, will continue at full capacity at least through October of 2001, at which time Lilly has the option to extend for up to two additional years. Since Read more about Millennium And Lilly Extend Collaboration[…]